PF-07265807 | Interleukin Related interleukin-related.com

Product Name :
PF-07265807

Search keywords :
PF-07265807

drugId :
null

Target Vo:
AXL receptor tyrosine kinase

Target Vo Short Name :
AXL

Moa_Name:
AXL receptor tyrosine kinase inhibitors

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
Pfizer Inc

Active Company_Name :
Pfizer Inc

Active Indication_Name:
Neoplasm Metastasis

In Active Indication_Name:
Solid tumours

Termination Status :

China Termination Status :

Highest Status:
Phase 1 Clinical

China Highest Status:
Phase 1 Clinical

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Alemtuzumab medchemexpress
Ravulizumab Description
RSK1 p90 Antibody (YA088): RSK1 p90 Antibody (YA088) is a non-conjugated and Rabbit origined monoclonal antibody about 83 kDa, targeting to RSK1 p90. It can be used for WB,ICC,IHC-P,FC assays with tag free, in the background of Human, Mouse, Rat.

Author: Interleukin Related

Related Posts